Drugmaker Eisai to withdraw weight loss drug Belviq after trials find cancer link

Clinical trials showed use of the drug increased the risk of a number of cancers, including pancreatic, colorectal and lung, the FDA said.

(CNN)Eisai Co. will withdraw its weight loss drug Belviq after the US Food and Drug Administration said clinical trials showed an increased incidence of cancer among users, the company said.

The FDA had asked Eisai to take Belviq and Belviq XR off the